With perfect timing, Hillary Clinton's presidential campaign announced a proposal to impose federal price controls on prescription drugs the day after Turing Pharmaceuticals declared it was raising the price of Daraprim, a medicine to combat the "toxoplasmosis" parasite, from $13.50 to $750 per pill.
Politically, Clinton may be on to something: In an August poll conducted by the Kaiser Family Foundation nearly three quarters of respondents said prescription costs are "unreasonable." Four in ten favored government regulation to keep costs down.
Daraprim's huge price increase, which was condemned by the pharmaceutical industry, has nevertheless thrust prescription drug prices into the political limelight after years of calm.
Read the entire op-ed at the Washington Examiner.
Research and commentary from a former senior executive in the U.S. Department of Health & Human Services
No comments:
Post a Comment